First Cardiology Clinic, Medical School, National and Kapodistrian University of Athens, Hippokration Hospital, Athens, Greece.
First Cardiology Clinic, Medical School, National and Kapodistrian University of Athens, Hippokration Hospital, Athens, Greece.
Curr Opin Pharmacol. 2018 Apr;39:35-42. doi: 10.1016/j.coph.2018.01.009. Epub 2018 Feb 22.
Peripheral artery disease (PAD) affects more than 200 million people worldwide. Hypertension has been related to increased risk of PAD. The treatment of elevated blood pressure (BP) in these patients is indicated to lower the cardiovascular risk with a BP goal of less than 130/80mmHg. Although there is no evidence that one class of antihypertensive medication or strategy is superior for BP lowering in PAD, the use of renin-angiotensin-system (RAS) inhibitors can be effective to reduce the cardiovascular risk. Beta-blockers (BBs) are not contraindicated. In the presence of carotid atherosclerosis, calcium-channel blockers (CCBs) and angiotensin-converting-enzyme inhibitors are recommended. In fibromuscular dysplasia the treatment of choice is percutaneous renal angioplasty. In renal artery disease optimal medical therapy includes RAS inhibitors, CCBs, BBs and diuretics.
外周动脉疾病（PAD）影响着全球超过 2 亿人。高血压与 PAD 风险增加有关。治疗这些患者的高血压（BP）以降低心血管风险，目标血压低于 130/80mmHg。虽然没有证据表明一种降压药物或策略在 PAD 中更有效，但肾素-血管紧张素系统（RAS）抑制剂的使用可以有效降低心血管风险。β受体阻滞剂（BBs）并非禁忌。在颈动脉粥样硬化的情况下，建议使用钙通道阻滞剂（CCBs）和血管紧张素转换酶抑制剂。在纤维肌性发育不良中，经皮肾血管成形术是首选治疗方法。在肾动脉疾病中，最佳的药物治疗包括 RAS 抑制剂、CCBs、BBs 和利尿剂。
